celecoxib and valdecoxib

celecoxib has been researched along with valdecoxib in 128 studies

Research

Studies (128)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	82 (64.06)	29.6817
2010's	44 (34.38)	24.3611
2020's	2 (1.56)	2.80

Authors

Authors	Studies
Brown, DL; Carter, JS; Graneto, MJ; Koboldt, CM; Masferrer, JL; Perkins, WE; Rogers, RS; Seibert, K; Shaffer, AF; Talley, JJ; Zhang, YY; Zweifel, BS	1
Baurin, N; Chavatte, P; Lesieur, D; Marot, C; Yous, S	1
Abbate, F; Casini, A; Ciattini, S; Coetzee, A; Scozzafava, A; Supuran, CT	1
Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A	1
Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS	1
Augustyniak, M; Bandarage, UK; Earl, RA; Ellis, JL; Garvey, DS; Janero, DR; Letts, LG; Martino, AM; Murty, MG; Ranatunge, RR; Richardson, SK; Schroeder, JD; Shumway, MJ; Tam, SW; Trocha, AM; Young, DV	1
Beswick, P; Bingham, S; Bountra, C; Brown, T; Browning, K; Campbell, I; Chessell, I; Clayton, N; Collins, S; Corfield, J; Guntrip, S; Haslam, C; Lambeth, P; Lucas, F; Mathews, N; Murkit, G; Naylor, A; Pegg, N; Pickup, E; Player, H; Price, H; Stevens, A; Stratton, S; Wiseman, J	1
Casini, A; Ferry, JG; Innocenti, A; Scozzafava, A; Supuran, CT; Zimmerman, S	1
Antel, J; Firnges, MA; Innocenti, A; Scozzafava, A; Supuran, CT; Wurl, M	1
D'Ambrosio, K; De Simone, G; Di Fiore, A; Pedone, C; Scozzafava, A; Supuran, CT	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Cecchi, A; Minakuchi, T; Nishimori, I; Onishi, S; Scozzafava, A; Supuran, CT; Vullo, D	1
Fischer, J; Gyires, K; Kis-Varga, A; Szabó, G	1
Anzellotti, P; Anzini, M; Biava, M; Botta, M; Cappelli, A; Ghelardini, C; Giordani, A; Makovec, F; Manetti, F; Norcini, M; Patrignani, P; Pergola, C; Rossi, A; Rovini, M; Sautebin, L; Vomero, S	1
Arslan, O; Aydin, M; Guler, OO; Innocenti, A; Isik, S; Kockar, F; Scozzafava, A; Supuran, CT	1
Hilvo, M; Innocenti, A; Kulomaa, MS; Parkkila, S; Salzano, AM; Scaloni, A; Scozzafava, A; Supuran, CT	1
Minakuchi, T; Nishimori, I; Scozzafava, A; Supuran, CT; Vullo, D	2
Innocenti, A; Minakuchi, T; Nishimori, I; Scozzafava, A; Supuran, CT; Vullo, D	1
Hall, RA; Innocenti, A; Mühlschlegel, FA; Schlicker, C; Scozzafava, A; Steegborn, C; Supuran, CT	1
Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO	1
Bertucci, A; Innocenti, A; Scozzafava, A; Supuran, CT; Tambutté, S; Zoccola, D	2
Carta, F; Covarrubias, AS; Jones, TA; Maresca, A; Mowbray, SL; Supuran, CT	1
Joseph, P; Köhler, S; Minakuchi, T; Montero, JL; Nishimori, I; Ouahrani-Bettache, S; Scozzafava, A; Supuran, CT; Turtaut, F; Vullo, D; Winum, JY	1
Joseph, P; Köhler, S; Minakuchi, T; Montero, JL; Nishimori, I; Ouahrani-Bettache, S; Scozzafava, A; Supuran, CT; Vullo, D; Winum, JY	1
Katsu, T; Matoyama, M; Miyata, K; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N	1
Innocenti, A; Knaus, EE; Scozzafava, A; Supuran, CT	1
Jackson, DJ; Ohradanova, A; Pastorek, J; Pastorekova, S; Supuran, CT; Vullo, D; Wörheide, G	1
Hewitson, KS; Mastrolorenzo, A; Scozzafava, A; Supuran, CT; Vullo, D	1
Capasso, C; Carginale, V; Luca, VD; Rossi, M; Scozzafava, A; Supuran, CT; Vullo, D	1
Aggarwal, M; Da Settimo, F; La Motta, C; Maresca, A; Marini, AM; McKenna, R; Nencetti, S; Nuti, E; Orlandini, E; Rossello, A; Salerno, S; Scozzafava, A; Simorini, F; Supuran, CT; Taliani, S	1
Capasso, C; Carginale, V; De Luca, V; Del Prete, S; Isik, S; Scozzafava, A; Supuran, CT; Vullo, D	1
Capaci Rodrigues, G; Capasso, C; Pan, P; Parkkila, S; Scozzafava, A; Supuran, CT; Tolvanen, ME; Vermelho, AB	1
Dalvie, D; Loi, CM; Smith, DA	1
Capasso, C; Leewattanapasuk, W; Mastrolorenzo, A; Mühlschlegel, FA; Supuran, CT; Vullo, D	1
Carta, F; Sethi, KK; Supuran, CT; Tanç, M; Verma, SM	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Carta, F; Sethi, KK; Supuran, CT; Tanç, M; Verma, SM; Vullo, D	1
Capasso, C; Corte-Real, S; Pan, P; Parkkila, S; Rodrigues, Ide A; Salonen, T; Supuran, CT; Syrjänen, L; Vermelho, AB; Vullo, D	1
Chimirri, A; Damiano, FM; De Luca, L; Ferro, S; Gitto, R; Supuran, CT; Vullo, D	1
Alothman, Z; Capasso, C; De Luca, V; Del Prete, S; Osman, SM; Scozzafava, A; Supuran, CT; Vullo, D	2
Calafato, G; Carta, F; Purper, G; Sethi, KK; Supuran, CT; Tanç, M; Verma, SM	1
Capasso, C; Minakuchi, T; Nishimori, I; Scozzafava, A; Supuran, CT; Vullo, D	1
AlOthman, Z; Capasso, C; Osman, SM; Prete, SD; Scozzafava, A; Supuran, CT; Vullo, D	1
Andrews, KT; Capasso, C; Del Prete, S; Fisher, GM; Poulsen, SA; Supuran, CT; Vullo, D	1
Capasso, C; Carginale, V; De Luca, V; Del Prete, S; Scozzafava, A; Supuran, CT; Vullo, D	2
Kuuslahti, M; Parkkila, S; Supuran, CT; Syrjänen, L; Tolvanen, M; Vullo, D	1
Capasso, C; Dedeoglu, N; DeLuca, V; Isik, S; Kockar, F; Supuran, CT; Yildirim, H	1
Cincinelli, A; Martellini, T; Supuran, CT; Vullo, D	1
Bhatt, A; Mahon, BP; McKenna, R; Supuran, CT; Vullo, D	1
AlOthman, Z; Capasso, C; Carginale, V; De Luca, V; Del Prete, S; Osman, SM; Scozzafava, A; Supuran, CT; Vullo, D	1
AlOthman, Z; Capasso, C; Carginale, V; De Luca, V; Del Prete, S; Ferraroni, M; Osman, SM; Supuran, CT; Vullo, D	1
Aşık, A; Beldüz, AO; Çanakçı, S; Çolak, DN; Eminoğlu, A; Supuran, CT; Vullo, D	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
AlOthman, Z; Capasso, C; Carginale, V; De Luca, V; Del Prete, S; Osman, SM; Supuran, CT; Vullo, D	2
Ramajayam, R	1
Jaswal, S; Kumar, S; Monga, V; Rulhania, S	1
Gierse, JK; Isakson, PC; Kiefer, JR; Koboldt, CM; Kurumbail, RG; Moreland, KT; Seibert, K; Walker, MC	1
Ouellet, M; Percival, MD; Riendeau, D	1
FitzGerald, GA	2
Hardy, KJ; McMurray, RW	1
Hayes, EC; Rock, JA	1
Gierse, JK; Hood, WF; Isakson, PC; Kiefer, JR; Kurumbail, RG; Monahan, JB; Seibert, K	1
Carter, J; Gierse, J; Hood, B; Isakson, P; Kiefer, J; Koboldt, C; Kurumbail, R; Marnett, L; Monahan, J; Moreland, K; Pawlitz, J; Pierce, J; Rowlinson, S; Seibert, K; Stegeman, R; Stevens, A; Talley, J; Walker, M	1
Laskin, B; Pashos, C; Peña, B; Stephens, J; Wong, J	1
Burian, M; Geisslinger, G	1
Blumenthal, M; Chen, TC; Kardosh, A; Schönthal, AH; Wang, WJ	1
Møiniche, S; Rømsing, J	1
Chan, VS	1
Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B	1
Boggie, DT; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG; Tran, F	1
Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y	1
Topol, EJ	1
Meena, S; Nagaraju, D; Rao, AR; Rao, RN	1
Furberg, CD; Psaty, BM	1
Drazen, JM	1
Wadman, M	2
Couzin, J	1
Okie, S	1
Romanovsky, AA	1
Cotter, J; Wooltorton, E	1
Vanchieri, C	1
Albini, A; Noonan, DM	1
Hochberg, MC	1
Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC	1
Epstein, RA	1
Cohen, JS	1
Cantilena, LR; Carlsson, U; Hammarström, P; Knudsen, JF; Sokol, GH	1
Bonnel, R; Brinker, A; Governale, L; Karwoski, C; La Grenade, L; Lee, L; Weaver, J	1
Meechan, J	1
Epstein, J; Klasser, GD	1
Gherardi, CR	1
Fraunfelder, FW; Mehelas, TJ; Solomon, J	1
Dogné, JM; Hanson, J; Pratico, D; Supuran, C	1
Ciddi, V; Keshetty, S; Molmoori, V; Venisetty, RK	1
Bhatia, S; Seedher, N	1
Furberg, CD	1
Bohn, L; Sadée, W	1
Macrì, R; Manfredi, C	1
Deray, G; Montalescot, G; Sibilia, J	1
Deray, G; Héloire, F; Valat, JP	1
Jugdutt, BI	1
Macedo, GM; Medeiros, BA; Nobre-e-Souza, MA; Palheta-Junior, RC; Santos, AA; Santos, CL; Souza, MH; Troncon, LE	1
Tabrizchi, R	1
Ashcroft, DM; Chen, LC	1
Bombardier, C; Coombs, JH; Copley-Merriman, C; Evans, C; Katz, N; Markman, J; Robbins, J; Simon, LS; West, C	1
Chen, E; Li, C; Maguluri, S; Recchia, FM	1
DeAngelis, CD; Thornton, JP	1
Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J	1
Boutary, M; Dorr, LD; Long, WT; Raya, J; Sirianni, LE	1
Simon, LS; White, WB	1
Elliott, WJ	1
Ashok, V; Dash, C; Rohan, TE; Sprafka, JM; Terry, PD	1
Honjo, H; Iwamoto, K; Uwai, Y	1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y	1
Hansen, SH; Skonberg, C; Syed, M	1
Cooper, AR; Dileep Kumar, JS; Mann, JJ; Matthew, J; Parsey, RV; Prabhakaran, J; Rubin-Falcone, H; Simpson, NR; Underwood, M; Zanderigo, F	1
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K	1

Reviews

19 review(s) available for celecoxib and valdecoxib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Medicinal chemistry of vicinal diaryl scaffold: A mini review. European journal of medicinal chemistry, 2019, Jan-15, Volume: 162 Topics: Carbonic Anhydrase IV; Chemistry, Pharmaceutical; Cyclooxygenase 2 Inhibitors; Drug Discovery; Humans; Hydrocarbons, Aromatic; Structure-Activity Relationship	2019
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Acetazolamide; Animals; Antineoplastic Agents; Antioxidants; Benzenesulfonamides; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Indoles; Isatin; Molecular Docking Simulation; Organoselenium Compounds; Oxadiazoles; Protein Binding; Protein Isoforms; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Thiazines; Thiophenes; Urea	2021
Cox-2 inhibitors: today and tomorrow. The American journal of the medical sciences, 2002, Volume: 323, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones	2002
COX-2 inhibitors and their role in gynecology. Obstetrical & gynecological survey, 2002, Volume: 57, Issue:11 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Dysmenorrhea; Endometriosis; Female; Genital Diseases, Female; Humans; Infertility, Female; Isoenzymes; Isoxazoles; Labor, Obstetric; Membrane Proteins; Menorrhagia; Menstrual Cycle; Ovary; Ovulation; Pain; Polycystic Ovary Syndrome; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides	2002
The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost of Illness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality of Life; Sulfonamides; Sulfones; Treatment Outcome	2003
[Clinical pharmacology of the selective COX-2 inhibitors]. Der Orthopade, 2003, Volume: 32, Issue:12 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones	2003
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Pain Measurement; Pain, Postoperative; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome	2004
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. Drug safety, 2004, Volume: 27, Issue:7 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
First and second generations of COX-2 selective inhibitors. Mini reviews in medicinal chemistry, 2004, Volume: 4, Issue:6 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2004
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome	2005
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. Journal (Canadian Dental Association), 2005, Volume: 71, Issue:8 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones; Toothache	2005
Coxibs and cardiovascular side-effects: from light to shadow. Current pharmaceutical design, 2006, Volume: 12, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2007
COX-2 selective inhibitors and heart health. Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones	2005
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones	2010
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones	2014

Trials

4 trial(s) available for celecoxib and valdecoxib

Article	Year
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13 Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxygenase 2; Drug Utilization Review; Endpoint Determination; Female; Hospitals, Veterans; Humans; Isoenzymes; Isoxazoles; Lactones; Male; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Therapeutic Equivalency	2004
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003. The British journal of oral & maxillofacial surgery, 2006, Volume: 44, Issue:2 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction	2006
Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. Die Pharmazie, 2006, Volume: 61, Issue:3 Topics: Adult; Area Under Curve; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Half-Life; Humans; Isoxazoles; Male; Pyrazoles; Sulfonamides	2006
Multimodal analgesia without parenteral narcotics for total knee arthroplasty. The Journal of arthroplasty, 2008, Volume: 23, Issue:4 Topics: Administration, Oral; Amides; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthetics, Local; Arthroplasty, Replacement, Knee; Aspirin; Catheters, Indwelling; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Femoral Nerve; Hip Joint; Humans; Injections, Intra-Articular; Isoxazoles; Ketorolac; Nerve Block; Pain Measurement; Pain, Postoperative; Prospective Studies; Pyrazoles; Ropivacaine; Sulfonamides	2008

Other Studies

105 other study(ies) available for celecoxib and valdecoxib

Article	Year
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of medicinal chemistry, 2000, Mar-09, Volume: 43, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyclooxygenase 2; Edema; Enzyme Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Recombinant Proteins; Sulfonamides	2000
Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. Journal of medicinal chemistry, 2001, Sep-27, Volume: 44, Issue:20 Topics: Benzene Derivatives; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopentanes; Imidazoles; Isoenzymes; Isoxazoles; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Quantitative Structure-Activity Relationship; Spiro Compounds; Thiophenes	2001
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorganic & medicinal chemistry letters, 2004, Jan-19, Volume: 14, Issue:2 Topics: Antipsychotic Agents; Binding Sites; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Crystallography, X-Ray; Humans; Isoenzymes; Sulpiride	2004
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. Journal of medicinal chemistry, 2004, Jan-29, Volume: 47, Issue:3 Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones	2004
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship	2004
Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. Journal of medicinal chemistry, 2004, Apr-22, Volume: 47, Issue:9 Topics: Administration, Oral; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Gastritis; Humans; In Vitro Techniques; Isoenzymes; Male; Membrane Proteins; Nitrates; Nitric Oxide Donors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2004
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2004, Nov-01, Volume: 14, Issue:21 Topics: Administration, Oral; Animals; Arthritis, Experimental; Biological Availability; Brain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Freund's Adjuvant; Humans; Infusions, Intravenous; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridazines; Rats; Structure-Activity Relationship	2004
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorganic & medicinal chemistry letters, 2004, Dec-20, Volume: 14, Issue:24 Topics: Archaea; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Isoenzymes; Molecular Structure; Structure-Activity Relationship; Sulfonamides	2004
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorganic & medicinal chemistry letters, 2005, Feb-15, Volume: 15, Issue:4 Topics: Animals; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IV; Cattle; Dose-Response Relationship, Drug; Humans; Isoenzymes; Kinetics; Membrane Proteins; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2005
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. Bioorganic & medicinal chemistry letters, 2006, Jan-15, Volume: 16, Issue:2 Topics: Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Isoenzymes; Isoxazoles; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Topoisomerase II Inhibitors	2006
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorganic & medicinal chemistry, 2007, Dec-01, Volume: 15, Issue:23 Topics: Amino Acid Sequence; Carbonic Anhydrase III; Carbonic Anhydrase Inhibitors; Cloning, Molecular; Cytosol; Enzyme Activation; Humans; Isoenzymes; Kinetics; Molecular Sequence Data; Recombinant Proteins; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2007
New celecoxib derivatives as anti-inflammatory agents. Journal of medicinal chemistry, 2008, Jan-10, Volume: 51, Issue:1 Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Edema; Ethanol; Gastric Mucosa; Hyperalgesia; Male; Pyrazoles; Rats; Rats, Wistar; Recombinant Proteins; Stereoisomerism; Stomach Ulcer; Sulfonamides	2008
Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. Journal of medicinal chemistry, 2008, Aug-14, Volume: 51, Issue:15 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Computer Simulation; Cyclooxygenase 2 Inhibitors; Edema; Ether; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Molecular Structure; Pyrroles; Rats; Structure-Activity Relationship	2008
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. Bioorganic & medicinal chemistry, 2009, Feb-01, Volume: 17, Issue:3 Topics: Amino Acid Sequence; Antifungal Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Kinetics; Molecular Sequence Data; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Sulfonamides; Sulfonic Acids	2009
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. Journal of medicinal chemistry, 2009, Feb-12, Volume: 52, Issue:3 Topics: Animals; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Isoenzymes; Kidney; Mice; Protein Processing, Post-Translational	2009
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. Journal of medicinal chemistry, 2009, Apr-23, Volume: 52, Issue:8 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Catalysis; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Humans; Molecular Sequence Data; Mycobacterium tuberculosis; Recombinant Proteins; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2009
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9 Topics: Amino Acid Sequence; Biocatalysis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Molecular Sequence Data; Mycobacterium tuberculosis; Sulfonamides; Sulfonic Acids	2009
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. Bioorganic & medicinal chemistry, 2009, Jul-01, Volume: 17, Issue:13 Topics: Amino Acid Sequence; Antifungal Agents; Bacterial Proteins; Candida albicans; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cryptococcus neoformans; Helicobacter pylori; Humans; Models, Molecular; Molecular Sequence Data; Protein Binding; Protein Conformation; Sequence Alignment; Structure-Activity Relationship; Sulfonamides	2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones	2009
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorganic & medicinal chemistry, 2009, Jul-15, Volume: 17, Issue:14 Topics: Amino Acid Sequence; Animals; Anthozoa; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Molecular Sequence Data; Molecular Structure; Recombinant Proteins; Sequence Alignment; Sulfonamides	2009
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorganic & medicinal chemistry letters, 2009, Dec-01, Volume: 19, Issue:23 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Catalytic Domain; Drug Design; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2009
Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5 Topics: Amino Acid Sequence; Animals; Base Sequence; Brucella suis; Brucellosis; Carbonic Anhydrases; Cloning, Molecular; DNA, Bacterial; Humans; Kinetics; Molecular Sequence Data; Phylogeny; Polymerase Chain Reaction; Sequence Alignment; Sequence Analysis, DNA; Structure-Activity Relationship; Sulfonamides	2010
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2 Topics: Animals; Anions; Anthozoa; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Structure-Activity Relationship; Sulfonamides	2011
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorganic & medicinal chemistry, 2011, Feb-01, Volume: 19, Issue:3 Topics: Anti-Bacterial Agents; Brucella suis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Drug Design; Drug Discovery; Inhibitory Concentration 50; Kinetics; Sulfonamides; Sulfonic Acids	2011
Synthesis and biological evaluation of loxoprofen derivatives. Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cell Membrane Permeability; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gastric Mucosa; Phenylpropionates; Rats	2011
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. Bioorganic & medicinal chemistry, 2011, Aug-15, Volume: 19, Issue:16 Topics: Anti-Bacterial Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Salmonella Infections; Salmonella typhimurium; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2011
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cytosol; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Molecular Targeted Therapy; Neoplasms; Stereoisomerism; Structure-Activity Relationship; Sulfonamides	2011
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana. Bioorganic & medicinal chemistry, 2012, Feb-15, Volume: 20, Issue:4 Topics: Amino Acid Sequence; Animals; Carbonic Anhydrases; Cloning, Molecular; Fossils; Humans; Molecular Sequence Data; Porifera; Protein Binding; Sequence Alignment; Sulfonamides; Sulfonic Acids	2012
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7 Topics: Amino Acid Sequence; Animals; Antifungal Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Dermatomycoses; Fungal Proteins; Humans; Isoenzymes; Malassezia; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Recombinant Fusion Proteins; Scalp Dermatoses; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2012
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides. Bioorganic & medicinal chemistry, 2013, Mar-15, Volume: 21, Issue:6 Topics: Amino Acid Sequence; Bacteria; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Kinetics; Molecular Sequence Data; Phylogeny; Protein Binding; Recombinant Proteins; Sequence Alignment; Sulfonamides	2013
Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit α- and β-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms. Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22 Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Catalytic Domain; Crystallography, X-Ray; Humans; Isoenzymes; Models, Molecular; Molecular Structure; Protein Conformation; Pyrazoles; Structure-Activity Relationship; Sulfonamides	2012
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Journal of medicinal chemistry, 2012, Dec-13, Volume: 55, Issue:23 Topics: Amino Acid Sequence; Biocatalysis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; DNA; Electrophoresis, Polyacrylamide Gel; Molecular Sequence Data; Phylogeny; Sequence Homology, Amino Acid; Vibrio cholerae	2012
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. Journal of medicinal chemistry, 2013, Feb-28, Volume: 56, Issue:4 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Chagas Disease; Cloning, Molecular; Humans; Molecular Sequence Data; Phylogeny; Protozoan Proteins; Structure-Activity Relationship; Sulfhydryl Compounds; Sulfonamides; Thiadiazoles; Trypanocidal Agents; Trypanosoma cruzi	2013
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides. Bioorganic & medicinal chemistry letters, 2013, May-01, Volume: 23, Issue:9 Topics: Acetazolamide; Amino Acid Sequence; Antifungal Agents; Candida glabrata; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Kinetics; Molecular Sequence Data; Phylogeny; Protein Binding; Sequence Alignment; Structure-Activity Relationship; Sulfonamides; Sulfonic Acids	2013
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety. Bioorganic & medicinal chemistry, 2013, Sep-01, Volume: 21, Issue:17 Topics: Animals; Benzenesulfonamides; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Phthalimides; Protein Binding; Structure-Activity Relationship; Sulfonamides	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety. Bioorganic & medicinal chemistry, 2013, Oct-01, Volume: 21, Issue:19 Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Enzyme Activation; Humans; Models, Biological; Molecular Structure; Phthalimides; Protein Isoforms; Structure-Activity Relationship	2013
Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis. Journal of medicinal chemistry, 2013, Sep-26, Volume: 56, Issue:18 Topics: Amino Acid Sequence; Antiprotozoal Agents; Biocatalysis; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Leishmania infantum; Leishmaniasis; Molecular Sequence Data	2013
Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors. European journal of medicinal chemistry, 2014, Volume: 71 Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Drug Design; Humans; Molecular Docking Simulation; Structure-Activity Relationship	2014
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii. Bioorganic & medicinal chemistry letters, 2014, Jan-01, Volume: 24, Issue:1 Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Diatoms; Dose-Response Relationship, Drug; Molecular Structure; Structure-Activity Relationship; Sulfonamides	2014
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis. Bioorganic & medicinal chemistry letters, 2014, Jan-01, Volume: 24, Issue:1 Topics: Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Porphyromonas gingivalis; Structure-Activity Relationship; Sulfonamides	2014
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties. Bioorganic & medicinal chemistry, 2014, Mar-01, Volume: 22, Issue:5 Topics: Benzenesulfonamides; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Humans; Isoindoles; Isoquinolines; Molecular Docking Simulation; Protein Isoforms; Structure-Activity Relationship; Sulfonamides	2014
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila. Bioorganic & medicinal chemistry, 2014, Jun-01, Volume: 22, Issue:11 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Dose-Response Relationship, Drug; Legionella pneumophila; Molecular Sequence Data; Molecular Structure; Sequence Alignment; Structure-Activity Relationship; Sulfonamides	2014
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes. Bioorganic & medicinal chemistry, 2014, Sep-01, Volume: 22, Issue:17 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Dose-Response Relationship, Drug; Humans; Molecular Sequence Data; Molecular Structure; Phylogeny; Porphyromonas gingivalis; Structure-Activity Relationship; Sulfonamides	2014
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum. Bioorganic & medicinal chemistry, 2015, Feb-01, Volume: 23, Issue:3 Topics: Antimalarials; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Plasmodium falciparum; Structure-Activity Relationship; Sulfonamides	2015
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune. Bioorganic & medicinal chemistry, 2015, Apr-15, Volume: 23, Issue:8 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Molecular Sequence Data; Nostoc commune; Sequence Alignment; Sulfanilamide; Sulfanilamides; Sulfonamides; Thiazines; Thiophenes	2015
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides. Bioorganic & medicinal chemistry, 2015, May-15, Volume: 23, Issue:10 Topics: Amino Acid Sequence; Animals; Anopheles; Baculoviridae; Bicarbonates; Carbon Dioxide; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Gene Expression; High-Throughput Screening Assays; Insect Proteins; Insecticides; Kinetics; Molecular Sequence Data; Phylogeny; Protons; Recombinant Proteins; Sequence Alignment; Sf9 Cells; Spodoptera; Sulfanilamides	2015
Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans. Bioorganic & medicinal chemistry letters, 2015, Jun-01, Volume: 25, Issue:11 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Molecular Sequence Data; Molecular Structure; Phylogeny; Streptococcus mutans; Sulfonamides	2015
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis. Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17 Topics: Acclimatization; Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cold Temperature; Humans; Molecular Sequence Data; Phylogeny; Pseudoalteromonas; Sequence Alignment; Sulfonamides	2015
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus. Bioorganic & medicinal chemistry letters, 2015, Dec-01, Volume: 25, Issue:23 Topics: Animals; Anions; Antarctic Regions; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Enzyme Activation; Fishes; Molecular Structure; Sulfonamides	2015
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA. Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2 Topics: Anti-Bacterial Agents; Carbon Dioxide; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Gammaproteobacteria; Molecular Docking Simulation; Sulfonamides	2016
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea. Bioorganic & medicinal chemistry letters, 2016, Feb-15, Volume: 26, Issue:4 Topics: Alteromonadaceae; Anti-Bacterial Agents; Bacterial Proteins; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Kinetics; Phylogeny; Protein Binding; Sulfanilamide; Sulfanilamides	2016
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. Bioorganic & medicinal chemistry, 2016, Mar-01, Volume: 24, Issue:5 Topics: Amino Acid Sequence; Base Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cholera; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Sequence Data; Sulfonamides; Vibrio cholerae	2016
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13. Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7 Topics: Acetazolamide; Benzenesulfonamides; Carbonic Anhydrase I; Carbonic Anhydrase Inhibitors; Enterobacter; Enterobacteriaceae Infections; Humans; Methazolamide; Structure-Activity Relationship; Sulfonamides	2016
Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae. Bioorganic & medicinal chemistry letters, 2016, Apr-15, Volume: 26, Issue:8 Topics: Amino Acid Sequence; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activity Relationship; Sulfonamides; Vibrio cholerae	2016
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum. Bioorganic & medicinal chemistry letters, 2016, 09-01, Volume: 26, Issue:17 Topics: Amino Acid Sequence; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cloning, Molecular; Humans; Kinetics; Molecular Sequence Data; Plasmodium falciparum; Protein Isoforms; Protein Structure, Tertiary; Recombinant Proteins; Sequence Alignment; Structure-Activity Relationship; Sulfonamides	2016
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. The Biochemical journal, 2001, Aug-01, Volume: 357, Issue:Pt 3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Kinetics; Meloxicam; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Sulfonamides; Thiazines; Thiazoles	2001
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25 Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones	2001
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. The American journal of cardiology, 2002, Mar-21, Volume: 89, Issue:6A Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular System; Celecoxib; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Isoxazoles; Lactones; Male; Pyrazoles; Sulfonamides; Sulfones	2002
Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Molecular pharmacology, 2003, Volume: 63, Issue:4 Topics: Animals; Binding Sites; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sheep; Sulfonamides; Tritium	2003
Mechanism of inhibition of novel COX-2 inhibitors. Advances in experimental medicine and biology, 2002, Volume: 507 Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Kinetics; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sulfonamides; Time Factors	2002
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective]. MMW Fortschritte der Medizin, 2003, May-01, Volume: 145, Issue:18 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Treatment Outcome	2003
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glioblastoma; Humans; Indomethacin; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Sulindac	2004
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration	2004
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis, 2004, Volume: 177, Issue:2 Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles	2004
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA, 2005, Jan-19, Volume: 293, Issue:3 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration	2005
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. Biomedical chromatography : BMC, 2005, Volume: 19, Issue:5 Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Nabumetone; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones	2005
COX-2 inhibitors--lessons in drug safety. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
COX-2 inhibitors--a lesson in unexpected problems. The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
Vioxx may go back on sale after scraping past FDA panel. Nature, 2005, Feb-24, Volume: 433, Issue:7028 Topics: Celecoxib; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713 Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
A painkiller is pulled from the market. So what do you do now? Heart advisor, 2004, Volume: 7, Issue:12 Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Isoxazoles; Nonprescription Drugs; Pyrazoles; Sulfonamides	2004
Raising the safety bar--the FDA's coxib meeting. The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13 Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy? American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Humans; Intramolecular Oxidoreductases; Isoxazoles; Lactones; Microsomes; Prostaglandin-E Synthases; Pyrazoles; Sulfonamides; Sulfones	2005
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, May-10, Volume: 172, Issue:10 Topics: Canada; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Contraindications; Cyclooxygenase Inhibitors; Decision Making; Drug Approval; Humans; Isoxazoles; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; United States; United States Food and Drug Administration	2005
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Rescuing COX-2 inhibitors from the waste bin. Journal of the National Cancer Institute, 2005, Jun-01, Volume: 97, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Endothelial Cells; Humans; Isoxazoles; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A	2005
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. Biomedical chromatography : BMC, 2006, Volume: 20, Issue:1 Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones	2006
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale journal of health policy, law, and ethics, 2005,Summer, Volume: 5, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents	2005
How celecoxib could be safer, how valdecoxib might have been. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoxazoles; Pyrazoles; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration	2005
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Inflammation, 2004, Volume: 28, Issue:5 Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Isoxazoles; Pyrazoles; Structure-Activity Relationship; Sulfonamides	2004
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug safety, 2005, Volume: 28, Issue:10 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Pyrazoles; Stevens-Johnson Syndrome; Sulfonamides; Sulfones	2005
[Cyclooxygenase-2 inhibitors and the ethics of research]. Medicina, 2005, Volume: 65, Issue:5 Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Ethics, Research; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones	2005
Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:2 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Conjunctivitis; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Isoxazoles; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders	2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique. Pharmacological research, 2006, Volume: 54, Issue:2 Topics: Anilino Naphthalenesulfonates; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Fluorescent Dyes; Hydrogen-Ion Concentration; Isoxazoles; Molecular Structure; Protein Binding; Pyrazoles; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Sulfonamides; Temperature; Thermodynamics	2006
The COX-2 inhibitors--an update. American heart journal, 2006, Volume: 152, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2006
How specific are "target-specific" drugs? Celecoxib as a case in point. Molecular interventions, 2006, Volume: 6, Issue:4 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Isoxazoles; Lactones; Molecular Structure; Protein Binding; Pyrazoles; Sulfonamides; Sulfones	2006
[Cyclooxygenase inhibitors: a never ending story?]. Giornale italiano di cardiologia (2006), 2006, Volume: 7, Issue:7 Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Europe; Humans; Isoxazoles; Italy; Lactones; Liability, Legal; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Sulfonamides; Sulfones; Texas; United States; United States Food and Drug Administration	2006
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones	2006
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation, 2007, Jan-23, Volume: 115, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling	2007
Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats. Neurogastroenterology and motility, 2007, Volume: 19, Issue:3 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastric Emptying; Gastric Mucosa; Indomethacin; Isoxazoles; Ketorolac; Lactones; Male; Muscle, Smooth; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones	2007
Coxibs: can this class of drugs survive? Vascular health and risk management, 2005, Volume: 1, Issue:1 Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones	2005
Preliminary development of a responder index for chronic low back pain. The Journal of rheumatology, 2007, Volume: 34, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Focus Groups; Health Status Indicators; Humans; International Cooperation; Isoxazoles; Low Back Pain; Outcome Assessment, Health Care; Pyrazoles; Reproducibility of Results; Sulfonamides	2007
Use of cox-2 inhibitors in patients with retinal venous occlusive disease. Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Prevalence; Pyrazoles; Retinal Vein Occlusion; Retrospective Studies; Sulfonamides; Sulfones	2008
Crunch time for peer review in lawsuit. Nature, 2008, Mar-06, Volume: 452, Issue:7183 Topics: Celecoxib; Confidentiality; Drug Industry; Humans; Isoxazoles; Peer Review, Research; Periodicals as Topic; Pyrazoles; Sulfonamides; United States	2008
Preserving confidentiality in the peer review process. JAMA, 2008, Apr-23, Volume: 299, Issue:16 Topics: Advertising; Celecoxib; Confidentiality; Cyclooxygenase 2 Inhibitors; Disclosure; Drug Industry; Isoxazoles; Liability, Legal; Peer Review, Research; Pyrazoles; Sulfonamides; United States	2008
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States	2008
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:1 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Incidence; Isoxazoles; Lactones; Logistic Models; Middle Aged; Odds Ratio; Pyrazoles; Risk; Sulfonamides; Sulfones	2011
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5 Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis	2010
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria. Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32 Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones	2016
Radiosynthesis and in vivo evaluation of [ Bioorganic & medicinal chemistry letters, 2018, 08-01, Volume: 28, Issue:14 Topics: Animals; Brain; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Isoxazoles; Male; Molecular Structure; Papio; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sulfonamides	2018
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. BMC cancer, 2021, May-03, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway	2021